Benitec Biopharma (BNTC) EBITDA Margin (2019 - 2023)

Benitec Biopharma has reported EBITDA Margin for 5 years, with the latest figure at 65000.0% in Q2 2023.

• Quarterly EBITDA Margin changed N/A year-over-year to 65000.0% in Q2 2023, while the trailing twelve-month figure through Mar 2024 was 307028.57% (down 27869181.0% YoY) and the FY2023 annual result came in at 25441.33%, down 98380.0% from the prior year.
• EBITDA Margin fell to 65000.0% in Q2 2023 per BNTC's latest filing, from 8038.89% in the prior quarter.
• Over five years, EBITDA Margin peaked at 8248.57% in Q2 2020 and troughed at 379300.0% in Q1 2021.
• A 5-year average of 80620.4% and a median of 8038.89% in 2023 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2021 and 2022: EBITDA Margin slumped 37176071 bps in 2021, then soared 37209167 bps in 2022.
• Over 5 years, EBITDA Margin stood at 2741.56% in 2019, then sank by 11787 bps to 325900.0% in 2020, then surged by 94 bps to 19340.0% in 2021, then sank by 107 bps to 40071.43% in 2022, then tumbled by 62 bps to 65000.0% in 2023.
• According to Business Quant data, EBITDA Margin over the past three periods registered 65000.0%, 8038.89%, and 40071.43% for Q2 2023, Q1 2023, and Q4 2022 respectively.